m+Medelevator.RU
← Поиск публикаций
ChemMedChem · 2026

Triple-Negative Breast Cancer Versus Non-Triple-Negative Breast Cancer: The Impact of Pd and Pt Complexes on Basal-Like Triple-Negative Breast Cancer.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Martins Clara B, Marques Maria P M, Batista de Carvalho Luís A E, Batista de Carvalho Ana L M

Аннотация

Breast cancer (BC) is the most common cancer in women, with a high mortality. Triple-negative breast cancer (TNBC) is a biologically aggressive tumour, characterised by high rates of metastasis. Improved chemotherapeutic approaches against BC are therefore an urgent clinical need. In this study, complexes with two and three metal centres linked by the biogenic polyamines: putrescine (Pt2Put2(NH3)4 and Pd2Put2) and spermidine (Pt3Spd2 and Pd3Spd2), as well as cisplatin were tested against non-malignant (MCF-12A), a TNBC (MDA-MB-468) and a non-TNBC (MCF-7) human cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Fourier transform infrared and Raman microspectroscopies allow to probe biological samples with unmatched sub-cellular spatial resolution. The results revealed that the polynuclear complexes showed activity for the TNBC cell line. While Pd3Spd2 showed significant impact on DNA (B-DNA to A- or Z-DNA), Pt2Put2(NH3)4 had a stronger effect on proteins (seen through Amide II vibrational mode). In addition, these complexes exhibited a greater impact on δC=C-H from phospholipids and CH2 deformations from lipids. For non-TNBC, Pd3Spd2 also displayed a strong contribution from Z-DNA (νOPObackbone), whereas Pt2Put2(NH3)4 had a significant impact on Amide I and Amide III signals. This knowledge is expected to contribute for the rational design of improved anticancer drugs, with a higher efficiency coupled to lower toxicity.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты